ClinicalTrials.gg
RecruitingNCT06852222cAMeLot-2Updated Nov 3, 2026

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

A Phase 3 interventional study of Bleximenib and Venetoclax (VEN) in Leukemia, Myeloid, Acute, sponsored by Janssen Research & Development, LLC. Recruiting at 270 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 3, 2026First site in South Africa9 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Leukemia, Myeloid, Acute by Johnson & Johnson — 2 open to participants now, 4 under way, 1 of them phase 3. Leukemia, Myeloid, Acute · Johnson & Johnson.

Planned enrollment
Largest of 15
600 · median 88
Started
2025
with 4 others
Phase 3
2 of 15
1 open now
Registered
14th of 15
by date

Among the 15 studies in Leukemia, Myeloid, Acute by Johnson & Johnson, this one has the largest planned enrollment, is one of 5 that started in 2025, is one of 2 in phase 3, and was the 14th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

2 of the 15 studies in Leukemia, Myeloid, Acute by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Leukemia, Myeloid, Acute by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene.

03

Conditions studied

  • Leukemia, Myeloid, Acute
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be 18 years of age or older at the time of
  • Previously untreated lysine N-methyltransferase 2A gene rearranged (KMT2Ar) or nucleophosmin 1 gene mutated (NPM1m) acute myeloid leukemia (AML) with greater than or equal to (> or =) 10% bone marrow blasts per 2022 international Consensus Classification criteria
  • Ineligible for intensive chemotherapy based on the following criteria: a) >= 75 years of age and ineligible per physician's discretion, with (ECOG) performance status of 0-2, b) >=18 to \<75 years of age with >= 1 of the following comorbidities: i) ECOG performance status of 2, ii) Severe cardiac disorder, iii) Severe pulmonary disorder, iv) Renal impairment, v) Moderate hepatic impairment vi) Comorbidity that, in the investigator's opinion, makes the participant unsuitable for intensive chemotherapy, which must be documented before enrollment as defined in the protocol. Ineligibility for intensive chemotherapy should be explicitly approved by a multidisciplinary team in countries in which this process is standard of care
  • Participants must have adequate hepatic and renal function
  • A female participant must agree not to be pregnant, breast-feed, plan to become pregnant and use protocol-specified while enrolled in this study and for 6 months after the last dose of study treatment
  • A male participant must agree to use protocol-specified contraception while enrolled in this study for at least 90 days after the last dose of study treatment
  • Must sign an informed consent form indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study

Exclusion criteria

Exclusion criteria:

  • Diagnosis of acute promyelocytic leukemia (APL)
  • Known active leukemic involvement of the central nervous system (CNS)
  • Recipient of solid organ transplant
  • Any cardiac disorders such as heart attack, uncontrolled/unstable chest pain, congestive heart failure, uncontrolled or symptomatic irregular heartbeat, blockage of a blood vessel to brain, or transient ischemic (decreased oxygen in tissue) attack within 6 months of randomization
  • Active infectious hepatitis
  • Live, attenuated vaccine within 4 weeks of randomization
  • Known allergies, , or intolerance of bleximenib, azacitidine, or venetoclax
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Arm A: Bleximenib and Venetoclax (VEN) + Azacitidine (AZA)

    Participants with acute myeloid leukemia (AML) will receive bleximenib in combination with venetoclax (VEN) and azacitidine (AZA) for 28-days treatment cycles and treatment will continue until progression or unacceptable toxicity.

    Drug: Bleximenib · Drug: Venetoclax (VEN) · Drug: Azacitidine (AZA)

  • Placebo comparator
    Arm B: Placebo and Venetoclax (VEN) + Azacitidine (AZA)

    Participants with AML will receive placebo in combination with VEN and AZA for 28-days treatment cycles, and treatment will continue until progression or unacceptable toxicity.

    Drug: Venetoclax (VEN) · Drug: Azacitidine (AZA) · Drug: Placebo

Interventions

  • Bleximenib will be administered orally.

    Also known as: JNJ-75276617

  • VEN will be administered orally.

  • AZA will be administered intravenously or subcutaneously.

  • DrugPlacebo

    Placebo will be administered orally.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants who Achieve Complete Remission (CR)

    CR is defined as Bone marrow blasts less than (\<) 5 percent (%); Absence of circulating blasts; Absence of extramedullary disease; Absolute neutrophil count (ANC) greater than or equal to (\>=) 1.0 \* 10\^9/Liter (1,000/microliter \[mcL\]); Platelet count \>= 100 \* 10\^9/L (100,000/mcL).

    Time frame: Up to 4 years and 1 month

  2. Overall Survival (OS)

    Overall survival time is defined as the time duration from the date of randomization to death due to any cause.

    Time frame: Up to 4 years and 1 month

Secondary outcomes

  1. Event-free survival (EFS)

    EFS is defined as the time from randomization to treatment failure, relapse, or death due to any cause, whichever occurs first.

    Time frame: Up to 4 years and 1 month

  2. Duration of CR

    Duration of CR will be estimated among responders from the date of initial documentation of CR, to the date of first documented evidence of relapse, or death due to any cause, whichever occurs first, respectively.

    Time frame: Up to 4 years and 1 month

  3. Time to CR

    Time to CR is defined as time from randomization to first documented response.

    Time frame: Up to 4 years and 1 month

  4. Rate of CR Without Measurable Residual Disease (MRD-)

    Rate of CR MRD- is defined as percentage of participants who have achieved CR without MRD.

    Time frame: Up to 4 years and 1 month

  5. Percentage of Participants who Achieved Transfusion Independence

    Transfusion independence is defined as lack of requirement for red blood cell (RBC) and platelet transfusions during any 56-day period.

    Time frame: Up to 4 years and 1 month

  6. Percentage of Participants with Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)

    Allo-HSCT rate is defined as the percentage of participants who have undergone allo-HSCT after randomization.

    Time frame: Up to 4 years and 1 month

  7. Number of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

    Time frame: Up to 4 years and 1 month

  8. Number of Participants with Abnormalities in Clinical Laboratory Parameters

    Participants with abnormalities in clinical laboratory parameters will be reported.

    Time frame: Up to 4 years and 1 month

  9. Serum Concentration of Bleximenib

    Serum samples will be analyzed to determine concentrations of bleximenib.

    Time frame: Up to 4 years and 1 month

07

Study locations

270 of 270 sites recruiting

Showing the first 100 of 270 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · innovativemedicine.jnj.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2029, 48 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's planned 48 months is above that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Feb 28, 2025
StartActual
Jun 4, 2025
Primary completionEst.
Jun 22, 2029
CompletionEst.
Aug 15, 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added, 1 site removed — first site in South Africa
Show 9 added (5 United States, 1 Hungary, 1 Denmark, 1 Japan, 1 South Africa)
  • Beth Israel Deaconess Medical Center · Boston, United States
  • Memorial Sloan Kettering Cancer Center · New York, United States
  • The University of Texas Health Science Center at Houston · Houston, United States
  • Debreceni Egyetem Klinikai Kozpont · Debrecen, Hungary
  • City of Hope Orange County Lennar Foundation Cancer Center · Irvine, United States
  • MaineHealth Institute for Research · South Portland, United States
  • Zealand University Hospital · Køge, Denmark
  • University of Tsukuba Hospital · Tsukuba, Japan
  • Haemalife · Cape Town, South Africa
Show 1 removed
  • Zealand University Hospital · Roskilde, Denmark
across 2 updates, Sep 25, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    5 sites added, 1 site removed — first site in South Africa
    Show 5 added (2 United States, 1 Denmark, 1 Japan, 1 South Africa)
    • City of Hope Orange County Lennar Foundation Cancer Center · Irvine, United States
    • MaineHealth Institute for Research · South Portland, United States
    • Zealand University Hospital · Køge, Denmark
    • University of Tsukuba Hospital · Tsukuba, Japan
    • Haemalife · Cape Town, South Africa
    Show 1 removed
    • Zealand University Hospital · Roskilde, Denmark
    + 1 other change: verification date
  2. Sep 25, 2026
    4 sites added
    Show 4 added (3 United States, 1 Hungary)
    • Beth Israel Deaconess Medical Center · Boston, United States
    • Memorial Sloan Kettering Cancer Center · New York, United States
    • The University of Texas Health Science Center at Houston · Houston, United States
    • Debreceni Egyetem Klinikai Kozpont · Debrecen, Hungary
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06852222
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
Jun 4, 2025
Primary completion
Jun 22, 2029 (estimated)
Completion
Aug 15, 2029 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bleximenib

Start the discussion